pharma · Alzheimer Disease · Amyotrophic Lateral Sclerosis · AMLX
Amylyx Pharmaceuticals EMEA
Amylyx Pharmaceuticals EMEA B.V.
Amylyx Pharmaceuticals EMEA clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 167
- Programs
- 7
- Drugs
- 2
- Patents
- 9
Amylyx Pharmaceuticals EMEA projects
7 ClinicalTrials.gov programs sponsored by Amylyx Pharmaceuticals EMEA.
Amylyx Pharmaceuticals EMEA has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AMX0035
Amylyx Pharmaceuticals EMEA B.V.
Progressive Supranuclear Palsy
1 trial -
AMX0035
Amylyx Pharmaceuticals EMEA B.V.
Amyotrophic Lateral Sclerosis
5 trials -
Avexitide
Amylyx Pharmaceuticals EMEA B.V.
Post Bariatric Hypoglycemia
1 trial -
AMX0035
Amylyx Pharmaceuticals EMEA B.V.
ALS
1 trial -
AMX0035
Amylyx Pharmaceuticals EMEA B.V.
Wolfram Syndrome
1 trial -
AMX0035
Amylyx Pharmaceuticals EMEA B.V.
Alzheimer Disease
1 trial -
AMX0114
Amylyx Pharmaceuticals EMEA B.V.
ALS
1 trial
Frequently asked questions
How many clinical projects does Amylyx Pharmaceuticals EMEA have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.